Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community blood DHT levels shot up after doubling dutasteride dosage

      in Finasteride/Dutasteride  20 upvotes 1 year ago
      A user increased their dutasteride dosage from 0.5mg to 1mg daily, resulting in a rise in DHT levels from 148 pg/mL to 281 pg/mL, and is considering switching back to finasteride due to continued hair loss. Replies suggest retesting and emphasize the importance of bloodwork before starting treatments.

      community long term ru58841 users (3 years+), how is it going for you?

      in Treatment  6 upvotes 8 months ago
      Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.

      community 6 weeks 5mg min 0.5mg dut progress

      in Progress Pictures  7 upvotes 11 months ago
      A 35-year-old man shares his positive progress in hair regrowth using a daily routine of 5mg oral minoxidil and 0.5mg dutasteride, along with a low light cap, weekly dermarolling, and biweekly ketoconazole shampoo. He reports noticeable improvements without side effects and aims to inspire others considering similar treatments.

      community Month 7. Dut/min/stemoxydine/microneedle. Nw7.

      in Progress Pictures  172 upvotes 1 year ago
      A user shared their 7-month progress on hair regrowth using a regimen of dutasteride, minoxidil, stemoxydine, microneedling, and keto shampoo. They noted significant improvement, particularly in vellus hair growth, and discussed the potential addition of RU58841, though they experienced side effects with it previously.

      community PP405 Phase 2a press release with early results

      in Research/Science  696 upvotes 9 months ago
      PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.